Biotelemetry is the remote and continuous assessment of physical and physiological characteristics.
This is becoming a useful tool in clinical trials, allowing GSK to collect patient data in real time.
Delivering Better Therapies With Cell Power The collaboration commenced with a three-year start-up phase that sees researchers initially focussing on three major projects.
They are: The laboratory’s projects mark the first convergence of a medical faculty in the UK with engineering-led solutions.
Although this is currently in a trial phase at the early stages of development, it could revolutionise the way drug trials are delivered.
With so much clinical research being evidence-based, biotelemetry increases confidence in a trial and ensures results are more accurate.This contributes to bringing new drugs to market sooner and at lower cost.These are cutting edge technologies for cutting edge projects – but Mc Laren’s expertise is equally useful in high volume production settings.For GSK the partnership represents the potential to catalyse transformational advances in the discovery, development and manufacture of future medicines.For Imperial, it represents yet another opportunity to deliver the cutting-edge research of the institute to an ever-larger section of society.One such example is the way in which we’ve helped GSK minimise downtime at a toothpaste factory.In motorsport, the lap chart isn’t the only place where speed is critical.We would also encourage other groups, including academics and pharmaceutical companies, to make their own compounds and related information publicly available.This is essentially an example of ‘open source’ being applied to drug discovery.One of the leading pharmaceutical companies in the world, Glaxo Smith Kline has surrendered all copyrights in its malarial data set, which includes more than 13,500 compounds known to be active against malaria.The data set is called Tres Cantos Antimalarial (TCAMS), and is available from the Ch EMBL-NTD database, "a repository for Open Access primary screening and medicinal chemistry data directed at neglected diseases - endemic tropical diseases of the developing regions of the Africa, Asia, and the Americas." Glaxo Smith Kline has surrendered all copyright in its malaria data set under the CC0 public domain dedication.